Knee Braces Market Size & Share 2026-2035

Knee Braces Market Size

The global knee braces market was valued at USD 1.15 billion in 2025, rising from USD 1.21 billion in 2026 to USD 1.81 billion by 2035 at a 4.6% CAGR from 2026 to 2035.

Knee braces serve distinct clinical and consumer needs: stabilizing ligament injuries, supporting post-operative recovery, redistributing load in osteoarthritic knees, and reducing injury exposure in sporting activity. This breadth makes the market less dependent on a single care setting than many orthopedic-device categories. Hospital protocols drive post-trauma and post-surgical use, while orthopedic clinics influence product selection for higher-value functional and unloader devices. Retail and online channels broaden access to lower-complexity sleeves and prophylactic products, although they provide less fitting support and generally carry lower average selling prices.

Osteoarthritis is the most durable source of clinically directed demand. The World Health Organization estimates that 528 million people were living with osteoarthritis in 2019, with the knee the most commonly affected joint and approximately 365 million people affected by knee osteoarthritis ^{[1]World Health Organization - Osteoarthritis, May 2023 - who.int}. A 2024 analysis of Global Burden of Disease data estimated 607 million prevalent osteoarthritis cases in 2021, underscoring the expanding pool of patients who may use bracing as part of conservative care. Aging reinforces this demand because osteoarthritis prevalence, mobility limitations, and the need for post-procedural rehabilitation all increase with age.

The market's projected growth rate is moderate because mature reimbursement-supported markets account for a large share of current value. Faster growth in Asia Pacific, Latin America, and the Middle East and Africa is supported by demographic aging, injury exposure, and expanding care access, but premium clinical braces remain less affordable where reimbursement is limited. Consequently, revenue growth depends not only on patient volumes, but also on whether manufacturers can convert demand toward clinically fitted, higher-value products.

This distinction explains why the 4.6% forecast CAGR is lower than the approximately 12% expansion recorded from 2022 to 2024. The historical period benefited from recovery in orthopedic and sports-related care demand, whereas the forecast reflects a more mature revenue base and persistent affordability constraints. Manufacturers that combine clinical evidence, fitting support, and differentiated product tiers are better positioned than suppliers competing solely on retail visibility or unit price.

Key Drivers

Osteoarthritis prevalence and conservative-care demand

Osteoarthritis creates recurring demand for functional and unloader braces because many patients require mobility support before surgery is considered, after surgery is delayed, or when surgery is clinically unsuitable. The high prevalence of knee involvement matters commercially: knee-focused products can be positioned around load management, stability, pain reduction, and continued participation in daily activities. Demand is strongest where orthopedic specialists can prescribe, fit, and monitor brace use rather than treating bracing as an undifferentiated retail purchase.

Trauma and sports-related knee injuries

Road trauma and sports injuries generate more immediate brace demand than chronic disease because stabilization is often required during recovery. The World Health Organization estimates 1.19 million annual road traffic deaths and between 20 million and 50 million nonfatal injuries worldwide ^{[2]World Health Organization - Road traffic injuries fact sheet, December 2023 - who.int}. Knee-injury exposure also rises with sporting participation. A long-run Australian analysis covering 228,344 knee injuries found increasing injury incidence over two decades, including growth in anterior cruciate ligament injuries. These events support functional and rehabilitative brace demand, while prevention-oriented sports participation supports prophylactic products.

Material, design, and connected-care innovation

Lighter frames, improved hinge systems, compression textiles, and improved fit can raise adherence by reducing bulk and restricting movement less severely. Connected rehabilitation systems may add value where clinicians need visibility into joint motion during home-based recovery. A 2024 pilot study demonstrated the feasibility of an IoT-enabled knee sleeve for continuous knee-angle monitoring in home rehabilitation. Such technologies remain at an early commercial stage, but they create a pathway for braces to function as part of remote rehabilitation rather than as passive support devices.

Population aging and participation in physical activity

Age-related osteoarthritis and post-operative care demand are expanding alongside the global older population. The United Nations projects that one in six people worldwide will be aged 65 years or older by 2050, compared with one in 11 in 2019. At the other end of the demand spectrum, broader fitness participation increases exposure to repetitive strain and acute injury. The Health & Fitness Association reported that global fitness industry revenue rose approximately 8% in 2024 and membership increased 6% across comparable markets. Together, these trends widen demand from older chronic-care patients and active users seeking prevention or recovery support.

Key Restraints

Premium-product affordability

Custom-fitted unloader braces, rigid ligament braces, and sensor-enabled products can cost substantially more than basic over-the-counter sleeves. The resulting price gap is especially consequential in markets where patients pay directly for orthopedic supports. Demand may still rise in those countries, but unit growth often concentrates in lower-priced compression or immobilization products rather than premium clinical devices. This limits revenue realization even when injury incidence and osteoarthritis prevalence are increasing.

Uneven reimbursement and referral infrastructure

Coverage frameworks shape whether a physician recommendation becomes an actual brace purchase. In the United States, Medicare covers certain knee orthoses under Local Coverage Determination L33318 when clinical criteria and documentation requirements are met ^{[3]Centers for Medicare & Medicaid Services - LCD: Knee Orthoses (L33318) - cms.gov}. These arrangements support demand for rigid and semi-rigid prescription products, including qualifying knee orthoses for ambulatory patients. Comparable infrastructure is less developed across much of Latin America, the Middle East and Africa, and parts of Asia Pacific, where treatment pathways may not consistently include specialist assessment, fitting, and follow-up.

Adherence and consumer understanding

A brace must be usable as well as clinically appropriate. Older patients and those with limited dexterity may struggle with complex closure systems, while active users may reject products that are heavy, restrictive, or visibly bulky. Lower awareness of rehabilitation options compounds this problem in markets with limited orthopedic referral capacity. Manufacturers therefore face a product-design and channel-education challenge: clinical performance alone does not ensure repeat use or successful adoption.

A tiered portfolio is therefore more important than a single global premium offering. Clinical-grade products require evidence, fitting capability, and reimbursement navigation, while accessible products require cost discipline and distribution reach. Suppliers that blur these requirements risk losing premium positioning in developed markets or failing to achieve conversion in price-sensitive markets.

Knee Braces Market Segment Analysis

By Product

Functional knee braces held the largest product share at 40.8% in 2025 and are projected to reach USD 680.9 million by 2035 at a 3.7% CAGR. Their leading position reflects broad utility across ligament instability, post-trauma stabilization, and recovery pathways. However, their comparatively slower growth reflects a maturing base and the increasing relevance of products designed for narrower clinical use cases.

Prophylactic braces are projected to be the fastest-growing product category at a 5.6% CAGR, reaching USD 593.5 million by 2035. The category benefits from organized sports participation and efforts to reduce injury exposure among active users. Product success depends on balancing protection with comfort and range of motion; a brace that impairs athletic performance is unlikely to achieve consistent use.

Unloader braces are projected to reach USD 335.6 million by 2035 at a 5.1% CAGR. They are closely linked to osteoarthritis management because they are designed to redistribute load away from the affected knee compartment. Clinical evidence can improve prescriber confidence. Bauerfeind reported that users of its GenuTrain OA brace experienced more than 40% pain reduction and a 50.6% increase in intensive physical activity over six weeks in a 2024 clinical study ^{[4]Bauerfeind Life - Clinical study using the GenuTrain OA knee brace, 2024 - bauerfeind-life.com}. Although individual product evidence should not be generalized across the category, it illustrates the type of outcome data that can support clinical adoption.

Rehabilitative braces are forecast to reach USD 204.7 million by 2035 at a 4.1% CAGR. Their demand base is tied to ligament reconstruction, meniscal repair, and arthroplasty recovery. Knee arthroplasty utilization across OECD countries increased at a 2.33% CAGR between 2011 and 2022, supporting a continuing procedural base for post-operative rehabilitation products ^{[5]PubMed - Utilization rates of knee arthroplasty in OECD countries, 2025 - pubmed.ncbi.nlm.nih.gov}.

By Application

Sports use generated USD 517.1 million in 2025 because sporting activity draws on prophylactic, functional, and rehabilitative braces. Ligament applications are projected to grow at a 5.4% CAGR and reach USD 627.6 million by 2035. This reflects demand from acute injury management, reconstruction recovery, and conservative treatment protocols where brace use is part of supervised care.

Other applications, including arthritis management, chronic instability, and post-fracture stabilization, are forecast to reach USD 424.4 million by 2035 at a 4.8% CAGR. This segment is anchored by chronic-care demand and is therefore less exposed to the variability of organized sports participation.

By End Use

Hospitals led end-use demand at USD 492.5 million in 2025, supported by trauma care, surgery-linked protocols, and institutional purchasing. Hospitals remain important for initial product selection, but procurement processes can favor established vendors able to meet contract, inventory, and service requirements.

Orthopedic clinics are forecast to be the fastest-growing end-use channel, expanding at a 5.3% CAGR to USD 766.5 million by 2035. Clinics are central to the fitted-brace market because they combine diagnosis, prescribing, product selection, and follow-up. Other end users, including physiotherapy practices, retail pharmacies, and direct-to-consumer channels, are expected to reach USD 297.1 million by 2035 at a 3.8% CAGR. These channels extend access but are more exposed to price comparison and limited product differentiation.

Retail and e-commerce channels remain relevant, particularly for simple sleeves and sports supports, but they do not replicate the economics of fitted clinical products. The strategic distinction is consequential: consumer channels reward brand recognition and price architecture, whereas specialty clinical channels reward evidence, product customization, and practitioner confidence.

Knee Braces Market Regional Analysis

North America

North America generated approximately USD 443 million in 2025, representing 38.5% of global revenue, and is projected to grow at a 3.81% CAGR. The United States accounted for USD 411.9 million in 2025, compared with USD 322.8 million in 2022, USD 335.8 million in 2023, and USD 397.1 million in 2024. Its 3.6% forecast CAGR reflects a mature market with established orthopedic care pathways rather than weak underlying demand. Medicare coverage for qualifying knee orthoses supports a more stable prescription base for clinical braces.

Europe

Europe recorded USD 304.2 million in 2025 and is expected to advance at approximately 4.36% CAGR. Germany is a major regional market because of its orthopedic manufacturing base and established prescribing environment. Across the region, product mix differs according to reimbursement depth: markets with stronger institutional coverage are better suited to premium functional and osteoarthritis-focused products, while more price-sensitive markets retain a larger over-the-counter component.

Asia Pacific

Asia Pacific generated USD 303.3 million in 2025 and is projected to expand at the fastest regional CAGR of 5.65%. China, Japan, South Korea, India, and Australia contribute different demand profiles. East and South Asia carry substantial osteoarthritis burdens ^{[6]Frontiers in Medicine - Global, regional, and national burdens of osteoarthritis from 1990 to 2021, 2024 - frontiersin.org}, while Japan and South Korea have more developed care infrastructure. China and India offer scale, but affordability and channel fragmentation limit rapid premium-product conversion. Australia adds an injury-led demand component, supported by documented increases in knee and ACL injury incidence ^{[7]PubMed Central - Trends in Australian knee injury rates: An epidemiological analysis of 228,344 knee injuries over 20 years, 2022 - pmc.ncbi.nlm.nih.gov}.

Latin America

Latin America accounted for USD 63.3 million in 2025 and is forecast to grow at approximately 5.17% CAGR. Brazil and Mexico anchor demand through their population scale, sports participation, and trauma-related recovery needs. However, limited reimbursement and high out-of-pocket exposure keep clinical-grade brace adoption below its potential. Road injury exposure adds to rehabilitation demand: the Americas recorded a road traffic fatality rate of 14.1 per 100,000 population in the World Health Organization's 2023 assessment.

Middle East & Africa

The Middle East and Africa market was valued at USD 38.0 million in 2025 and is expected to grow at approximately 5.59% CAGR. Saudi Arabia, the UAE, and South Africa lead regional demand through healthcare investment, sports medicine activity, and private-sector rehabilitation services. Growth starts from a low revenue base and remains sensitive to affordability, import dependence, and uneven reimbursement coverage.

Europe offers a different value proposition. Its growth is steadier, but reimbursement-supported specialist markets and a strong orthopedic manufacturing base support clinical-grade positioning. Latin America and the Middle East and Africa can add growth, yet their commercial significance will depend more heavily on improvements in care access and reimbursement than on epidemiology alone.

Knee Braces Market Share & Competitive Landscape

The market is moderately consolidated, with enovis, BAUERFEIND, OSSUR, BREG, and ottobock collectively accounting for approximately 37% of global revenue in 2025. Competition centers on clinical evidence, product breadth, reimbursement capability, practitioner access, and the ability to serve distinct price tiers rather than on product availability alone.

enovis competes through the DonJoy franchise in prescription-oriented orthopedic and sports medicine segments. In January 2024, the company introduced the DonJoy ROAM OA brace for unicompartmental osteoarthritis-related pain and instability ^{[8]Enovis Corporation - Enovis Introduces the DonJoy ROAM OA Knee Brace, January 25, 2024 - ir.enovis.com}. It also showcased the Defiance PRO custom carbon-fiber ligament brace at the 2024 American Orthopaedic Society for Sports Medicine annual meeting. These launches reinforce its presence in unloader and high-performance ligament bracing.

BAUERFEIND competes through compression, osteoarthritis, and ligament-support products supported by clinical positioning. OSSUR maintains a premium orthopedic focus across unloader and functional bracing, while BREG has established positions in post-operative rehabilitation and hospital-linked channels. ottobock brings orthopedic engineering depth and financial capacity; it reported preliminary 2024 revenue of more than EUR 1.6 billion, up 7% year over year, and adjusted EBITDA exceeding EUR 325 million ^{[9]Ottobock - Preliminary Business Figures 2024: 7 percent revenue growth and earnings increase of 17 percent, 2025 - corporate.ottobock.com}.

The remaining authorized participants broaden competitive coverage across clinical, retail, and regional channels: 3M, ALEX ORTHOPEDIC, Dicarre, essity, HELY & WEBER, MCDAVID, MEDI-DYNE, MEDLINE, MUELLER SPORTS MEDICINE, push braces, and tynor. Sports-oriented brands compete more directly in prophylactic and consumer-accessible categories, while healthcare distributors and specialty orthotics suppliers serve hospitals, clinics, rehabilitation practices, and localized fitting needs. tynor is particularly relevant to cost-accessible orthopedic product demand in India and surrounding markets.

Recent Industry Developments

In January 2024, enovis introduced the DonJoy ROAM OA knee brace, expanding its osteoarthritis-focused product portfolio with an unloader device designed for conservative care and pre- or post-surgical use.

In July 2024, enovis presented its Defiance PRO custom carbon-fiber ligament brace at the AOSSM Annual Meeting. The product incorporates an updated hinge system and a lower-profile frame intended for active users requiring ligament stabilization.

Bauerfeind publicized 2024 clinical results for GenuTrain OA, reporting pain reduction of more than 40% and a 50.6% increase in intensive physical activity after six weeks of use. The development is commercially relevant because product-specific clinical evidence can support specialist prescribing and reimbursement discussions.

Ottobock reported preliminary 2024 revenue exceeding EUR 1.6 billion and adjusted EBITDA of more than EUR 325 million in 2025, reflecting increased capacity to invest in orthotic technologies and market access initiatives.